Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 6/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21240474 | 0.78 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL29578418 | 0.78 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL21240303 | 0.78 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL21240302 | 0.78 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL29577779 | 0.78 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL17024320 | 0.77 | TTK (0.44) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL26942867 | 0.77 | TTK (0.43) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL21240060 | 0.76 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL21240061 | 0.76 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 | |
| SCHEMBL21240415 | 0.76 | TTK (0.35) | TTKCCNA2CDK2MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399327-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399327-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022089398-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | 杭州阿诺生物医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399327-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | MAP3K9, MAP3K1, MAP3K15 | TTK 124/4885CCNA2 2307/4885CDK2 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.